MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Funding Strategies for Architects (Private Equity, Venture & Risk Capital)
Intermediaries: Risk Capital (Angel, Seed, Venture Capital, SPAC, Strategic Corporate, Private Equity, Banking)
Intermediaries: Hedge Funds
*Hedge Funds (Medical, Biotechnology Focused)
Scopia Capital
Finance & Acquisitions: Scopia
Acorda Therapeutics, Inc. (NASDAQ:ACOR)*
Organization & Developments: Acorda
Parents
Acorda Therapeutics, Inc. (NASDAQ:ACOR)*
Children
2010: Ampyra was approved in January 2010 to improve the walking ability of people with MS
2011: Acorda Stock Halted as Shares Skyrocket on Patent Speculation (2011)
2011: Acorda Therapeutics Pays $35 Million for Medtronic, Inc. Drug, Fills Out Mid-Stage Neurology Pipeline (2011)
2011: RBC Capital Markets speculated in a report that the patent on the company’s multiple sclerosis (MS) drug, dalfampridine (Ampyra), might extend for longer than initially expected. (2011)
2012: Acorda’s top-selling drug is multiple sclerosis treatment Amphyra, which generated $210.5 million in 2011 revenue.
2013: Acorda Therapeutics Announces Department of Defense (DOD) Contract to Support Study of AC105 in Acute Spinal Cord Injury (2013)
2017: Acorda Puts 4 Drugs On Back Burner After Patent Setback
2017: FDA rejects Acorda's marketing application for Parkinson's candidate Inbrija; shares down 24% premarket - Acorda Therapeutics, Inc. (NASDAQ:ACOR)
2018: Acorda Gets Much Needed FDA Approval To Counter Patent Setback - Acorda Therapeutics, Inc. (NASDAQ:ACOR)
2018: Acorda Has Suffered 2 Setbacks, Both Of Which Can Be Dealt With - Acorda Therapeutics, Inc. (NASDAQ:ACOR)
2018: Biologics: Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts
2018: VA_65--Acorda Therapeutics, Inc. 420 Saw Mill River Rd. Ardsley, NY 10502
2019: Acorda Cuts Staff 25% and Restructures to Keep Focus on Parkinson’s Drug
2019: Acorda: Time To Catch The Falling Knife?_seekingalpha.com
2021: Acorda Therapeutics: Buying Before The Coast Is Clear
2024: Acorda inks $185M asset sale with Merz, files for bankruptcy after years of disappointing sales_ fiercepharma
Jumps
*Key People: Acorda
Finance & Acquisitions: Acorda